Explanipedia

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission Open

Nikos Viazis, Αναστάσιος Καραμανάκος, Konstantinos Mousourakis, Angeliki Christidou, Fotios S. Fousekis , et al. · 2025

Aim To report on the efficacy and safety of elective switching from intravenously (IV) to subcutaneously (SC) administered Infliximab (IFX) in patients with immune mediated diseases. Methods Retrospective analysis of patients with Crohn’s …

Induction with upadacitinib in Crohn’s disease: real-world experience from an early-access program in Greece Open

Evgenia Papathanasiou, Alexandros Ioannou, Pavlos Pardalis, G Leonidakis, George Michalopoulos , et al. · 2025

In a small cohort of resistant CD patients, the short-term clinical efficacy of upadacitinib was high.

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study Open

Ferdinando D’Amico, Luca Massimino, Giulia Palmieri, Arianna Dal Buono, Roberto Gabbiadini , et al. · 2024

Background and Aims Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV)…

P1086 Re-administration of infliximab in patients with extremely refractory perianal Crohn’s disease Open

K Mousourakis, C. Veretanos, Konstantinos G. Arvanitis, T. Georgiadi, G. Nousias , et al. · 2024

Background This study aims to evaluate the efficacy of infliximab re-administration to a cohort of patients with extremely refractory perianal Crohn's Disease (CD). Methods Retrospective analysis of prospectively collected data in CD patie…

Switching from Intravenous to Subcutaneous Infliximab in Patients with Immune Mediated Diseases in Clinical Remission Open

Nikos Viazis, Αναστάσιος Καραμανάκος, Konstantinos Mousourakis, Angeliki Christidou, Fotios S. Fousekis , et al. · 2024

P951 Efficacy and safety of tofacitinib for the treatment of moderate- severe ulcerative colitis in biologic naïve patients Open

Christos Liatsos, Giorgos D. Michalopoulos, Maria Tzouvala, Όλγα Γιουλεμέ, D Kozompoli , et al. · 2024

Background To assess the rates of clinical response at week 8, biochemical response, steroid-free clinical remission, endoscopic healing and safety data at week 26 of tofacitinib in biologic naive patients with moderate-severe ulcerative c…

P942 Real-world data on outcomes of treatment with ustekinumab in patients with Ulcerative Colitis Open

K Chalakatevaki, G Kokkotis, M L Chatzinikolaou, Evangelia Anagnostopoulou, K Argiriou , et al. · 2024

Background Ustekinumab (UST), a monoclonal antibody against the shared p40 subunit of IL-12/IL-23, has been approved for the treatment of moderate to severe ulcerative colitis (UC). The aim of this ambi-directional study is to collect and …

P723 Upadacitinib in Crohn’s disease: Real world experience from an early access program in Greece Open

Evangelos Papathanasiou, G Leonidakis, Georgios Michalopoulos, Spilios Manolakopoulos, Spyros I. Siakavellas , et al. · 2024

Background Upadacitinib is a novel selective Janus kinase 1 inhibitor, recently approved for the management of Crohn’s disease (CD) by Food and Drug Administration. In Greece, upadacitinib is available through an early access program for r…

CURCUMIN-QINGDAI COMBINATION FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED CLINICAL TRIAL Open

Shomron Ben‐Horin, Nir Salomon, G Karampekos, Nikos Viazis, Adi Lahat , et al. · 2023

BACKGROUND The herbal extracts Curcumin and QingDai were previously shown to be effective in mild-moderate and in moderate-severe ulcerative colitis (UC), respectively. We evaluated the efficacy and safety of a combination of curcumin-Qing…

Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY Open

Eirini Zacharopoulou, Eleni Orfanoudaki, Vassiliki Kitsou, Maria Tzouvala, George Tribonias , et al. · 2022

Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE Open

Eleni Orfanoudaki, Eirini Zacharopoulou, Vassiliki Kitsou, Konstantinos Κarmiris, Anǵeliki Theodoropoulou , et al. · 2022

The ulcerative colitis narrative Greece survey: patients’ and physicians’ perspective on quality of life and disease management Open

Nikos Viazis · 2022

Greek UC patients appear to be satisfied with their physicians and their disease management. Gaps in patient-physician communication relating to quality of life, emotional, and sexual/relationship concerns need to be addressed.

P235 The natural history of COVID-19 in vaccinated Inflammatory Bowel Disease patients Open

Nikos Viazis, A Theodoropoulou, Evangelia Zampeli, Konstantinos Κarmiris, Maria Tzouvala , et al. · 2022

Background Patients with Inflammatory Bowel Disease (IBD), especially those on immunosuppressive (IMS) treatment should be vaccinated against SARS-CoV-2 to prevent hospitalization, mechanical ventilation, and death. However, IMS may advers…

P429 Mesalazine has no place in the treatment of Crohn’s disease. Really? Open

G Mantzaris MD- PhD- AGAF- FEBG- MACG, Eleftherios Archavlis, Angeliki Christidou, Nikos Viazis, G Karampekos · 2022

Background According to international guidelines mesalazine may have no place in the treatment of Crohn’s disease (CD). However, real-world studies have shown a defined, 5-ASA-dependent group of patients with CD whereas a large proportion …

The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD. Open

Giorgos Bamias, Georgios Kokkotis, Angeliki Christidou, Dimitrios Christodoulou, Vasileios Delis , et al. · 2021

IBD patients who developed COVID-19 had a benign course with adverse outcomes being infrequent. Treatment with anti-TNF biologics had a protective effect, thus, supporting continuation of therapy during the pandemic.

Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy Open

Michail Galanopoulos, Aris Doukatas, F Gkeros, Nikos Viazis, Christos Liatsos · 2021

Pancreatic cancer is one of the highest and in fact, unchanged mortality-associated tumor, with an exceptionally low survival rate due to its challenging diagnostic approach. So far, its treatment is based on a combination of approaches (s…

Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission Open

Nikos Viazis, C Pontas, Anastassios C. Manolakis, G Karampekos, Emmanouela Tsoukali , et al. · 2021

Background-Aim : Intravenously administered biologicals are associated with a huge pressure to Infusion Units and increased cost. We aimed to assess the impact of switching infliximab to golimumab in ulcerative colitis (UC) patients in dee…

P096 Which patients with known Crohn’s disease after an ileo-colonoscopy will benefit most from small bowel capsule endoscopy? Open

Nikos Viazis, A. Mountaki, K Koustenis, C. Veretanos, K. Arvanitis , et al. · 2021

Background Ileo-colonoscopy with biopsies is considered the gold standard for the diagnosis and management of Crohn’s disease (CD). In contrast, the role of small bowel capsule endoscopy (SBCE) is limited currently in cases where ileo-colo…

P636 The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD Open

Giorgos Bamias, G Kokkotis, Dimitrios Christodoulou, Vassilios C. Delis, Anthia Gatopoulou , et al. · 2021

Background COVID-19 has evolved into a global health crisis, variably affecting the management of patients with chronic illnesses. Patients with inflammatory bowel disease (IBD) may represent a vulnerable population due to the frequent adm…

Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort Open

Giorgos Bamias, Georgios Kokkotis, Michalis Gizis, Christina Kapizioni, Konstantinos Κarmiris , et al. · 2021

Efficacy of Infliximab after Failure of Subcutaneous Anti-TNF Agents in Patients with Moderate to Severe Ulcerative Colitis Open

Nikos Viazis, C Pontas, George Karampekos, Emmanouela Tsoukali, Όλγα Γιουλεμέ , et al. · 2020

Aim: To assess the efficacy of infliximab in ulcerative colitis (UC) patients who had failed therapy with adalimumab or golimumab. Methods: Retrospective analysis of prospectively acquired data of all anti-TNF naive patients with moderate…

COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract Open

Michail Galanopoulos, F Gkeros, Aris Doukatas, Grigorios Karianakis, C Pontas , et al. · 2020

The pandemic of coronavirus disease 2019 (COVID-19), caused by a newly identified β-coronavirus (SARS-CoV-2) has emerged as a dire health problem, causing a massive crisis for global health. Primary method of transmission was firstly thoug…

Mo1634 COLD SNARE POLYPECTOMY VS HOT SNARE POLYPECTOMY VS ARGON PLASMA COAGULATION (APC) FOR 5-9 MM LEFT-SIDED COLORECTAL POLYPS: A PROSPECTIVE RANDOMIZED TRIAL Open

Lazaros Varytimiadis, Nikos Viazis, George Kyriakopoulos, Ioannis S. Papanikolaou, George Tribonias , et al. · 2020

P576 The value of small bowel capsule endoscopy in the change of therapeutic management in patients with established Crohn’s disease Open

Nikos Viazis, Emmanouela Tsoukali, C Pontas, G Karampekos, F Gkeros , et al. · 2020

Background Small bowel capsule endoscopy (SBCE) is widely used for various indications in patients with established Crohn’s disease (CD). Our aim was to investigate whether SBCE can lead to changes in the therapeutic management of CD patie…

Sa1793 – Evaluation of the 10-Year Cardiovascular Disease Death Risk in Greek Patients with Inflammatory Bowel Disease Open

Emmanouela Tsoukali, Aikaterini Μantaka, Kalliopi Foteinogiannopoulou, Nikos Viazis, Demosthenes B. Panagiotakos , et al. · 2019

P659 Efficacy of switching from infliximab to golimumab in ulcerative colitis patients on deep remission Open

Nikos Viazis, C Pontas, Maria Gazouli, T Tsigaridas, I Tziortziotis , et al. · 2019

Increasing number of patients with ulcerative colitis (UC) patients on infliximab (IFX) scheduled maintenance therapy constitute a burden to many infusion units. Elective and effective switching to subcutaneous golimumab (GLM) may at least…

P507 Efficacy of Infliximab after failure of subcutaneous anti-TNF agents in patients with moderate-to-severe ulcerative colitis Open

Nikos Viazis, Emmanouela Tsoukali, Michail Galanopoulos, C Pontas, G Karampekos , et al. · 2019

To assess the efficacy of intravenously administered infliximab in patients with moderate to severe ulcerative colitis (UC) who have failed therapy with subcutaneously administered adalimumab or golimumab. Retrospective analysis of prospec…

P796 Cardiovascular risk profile in Greek patients with inflammatory bowel disease Open

Emmanouela Tsoukali, Aikaterini Μantaka, Eleni Orfanoudaki, Nikos Viazis, Christos Pitsavos , et al. · 2019

Inflammatory bowel diseases (IBD) are linked with a higher risk for cardiovascular diseases (CVD) due to the contribution of chronic systemic inflammation in the pathogenesis of atherosclerosis. However, the separate role of the traditiona…

Su1254 FACTORS PREDICTING INCOMPLETE SMALL BOWEL CAPSULE ENDOSCOPY Open

Emmanouela Tsoukali, Christina Chatzievangelinou, Michail Galanopoulos, K. Katopodi, I Tziortziotis , et al. · 2018

P876 Prevalence of Clostridium difficile infection among hospitalised inflammatory bowel disease patients in Greece Open

Nikos Viazis, C Pontas, Eleni Belesiotou, Konstantinos Κarmiris, Ioannis Dimas , et al. · 2018

Clostridium difficile (C. difficile) is the leading cause of antibiotic-associated colitis and nosocomial diarrhoea. Patients with inflammatory bowel disease (IBD) are at increased risk of developing C. difficile infection (CDI); however, …

Nikos Viazis YOU? Author Swipe